CLVS Zooms To New High, FLML Gets Thumbs Up, SNTA Dives, STEM Grows RTT News According to the trial results, 40% of Rituximab-refractory patients achieved a complete response and 100% of marginal zone lymphoma patients achieved a complete or partial response. TGTX closed Monday's trading 2.34% down at $6.25. by RTT Staff ... |
